Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone

M. A. Cukierski, Andrew G Hendrickx, S. Prahalada, Alice F Tarantal, D. L. Hess, B. L. Lasley, C. P. Peter, R. Tarara, R. T. Robertson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Norfloxacin, an orally active fluoroquinolone antimicrobial, has been reported to be embryolethal but not teratogenic when administered to pregnant cynomolgus macaques prior to gestational day (GD) 36 at doses ≥200 mg/kg/day. Additional studies have been performed in an effort to examine the mechanism responsible for this effect, particularly regarding the role of progesterone (P). The first study (Study I) investigated the effect of norfloxacin administration during early pregnancy (200 mg/kg/day; daily GD 20-30) in the absence of a functional corpus luteum (CL). The CL was surgically removed from 16 gravid females on GD 19 in order to focus on placental-derived P; ten were dosed with norfloxacin and six received vehicle only. Embryolethality was observed for 7/10 (70%) of the treated animals during GD 25-31 versus 0/6 (0%) for controls. A reduction in serum P was noted prior to embryonic loss, although no significant effects on chorionic gonadotropin (CG), 17β-estradiol (E2), or P or E urinary metabolites were observed. A second study (Study II) was performed in order to evaluate the capacity of norfloxacin (200 mg/kg) to reduce CL-derived P in both normally cycling and CG-stimulated nonpregnant females (ten treated, ten controls; daily for 8 days). No effects on P production or on luteal phase or menstrual cycle lengths were observed. The third study (Study III) was designed to examine the effect of norfloxacin on the metabolism and excretion of P in nonpregnant females. Silastic P implants were placed subcutaneously in order to maintain constant P levels during a 10 day treatment regimen (200 mg/kg/day; ten controls, nine treated). Five of the controls and four of the norfloxacin-treated females also received 14C-P intravenously within 1 hr of the last dose of norfloxacin in order to study excretory patterns. No significant differences between control and treated groups were observed. The results of these studies combined suggest that the developmental toxic effects observed in prior studies and Study I are specific to pregnancy and directly related to placental-derived P production.

Original languageEnglish (US)
Pages (from-to)429-438
Number of pages10
JournalTeratology
Volume46
Issue number5
DOIs
StatePublished - 1992

Fingerprint

Norfloxacin
Macaca fascicularis
Progesterone
Corpus Luteum
Chorionic Gonadotropin
Pregnancy
Luteal Phase
Poisons
Fluoroquinolones
Macaca
Metabolites
Metabolism
Estradiol
Animals
Control Groups
Serum

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Cukierski, M. A., Hendrickx, A. G., Prahalada, S., Tarantal, A. F., Hess, D. L., Lasley, B. L., ... Robertson, R. T. (1992). Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone. Teratology, 46(5), 429-438. https://doi.org/10.1002/tera.1420460507

Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone. / Cukierski, M. A.; Hendrickx, Andrew G; Prahalada, S.; Tarantal, Alice F; Hess, D. L.; Lasley, B. L.; Peter, C. P.; Tarara, R.; Robertson, R. T.

In: Teratology, Vol. 46, No. 5, 1992, p. 429-438.

Research output: Contribution to journalArticle

Cukierski, MA, Hendrickx, AG, Prahalada, S, Tarantal, AF, Hess, DL, Lasley, BL, Peter, CP, Tarara, R & Robertson, RT 1992, 'Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone', Teratology, vol. 46, no. 5, pp. 429-438. https://doi.org/10.1002/tera.1420460507
Cukierski, M. A. ; Hendrickx, Andrew G ; Prahalada, S. ; Tarantal, Alice F ; Hess, D. L. ; Lasley, B. L. ; Peter, C. P. ; Tarara, R. ; Robertson, R. T. / Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone. In: Teratology. 1992 ; Vol. 46, No. 5. pp. 429-438.
@article{54c58b38c0c943a1b8e3baa6873f337d,
title = "Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone",
abstract = "Norfloxacin, an orally active fluoroquinolone antimicrobial, has been reported to be embryolethal but not teratogenic when administered to pregnant cynomolgus macaques prior to gestational day (GD) 36 at doses ≥200 mg/kg/day. Additional studies have been performed in an effort to examine the mechanism responsible for this effect, particularly regarding the role of progesterone (P). The first study (Study I) investigated the effect of norfloxacin administration during early pregnancy (200 mg/kg/day; daily GD 20-30) in the absence of a functional corpus luteum (CL). The CL was surgically removed from 16 gravid females on GD 19 in order to focus on placental-derived P; ten were dosed with norfloxacin and six received vehicle only. Embryolethality was observed for 7/10 (70{\%}) of the treated animals during GD 25-31 versus 0/6 (0{\%}) for controls. A reduction in serum P was noted prior to embryonic loss, although no significant effects on chorionic gonadotropin (CG), 17β-estradiol (E2), or P or E urinary metabolites were observed. A second study (Study II) was performed in order to evaluate the capacity of norfloxacin (200 mg/kg) to reduce CL-derived P in both normally cycling and CG-stimulated nonpregnant females (ten treated, ten controls; daily for 8 days). No effects on P production or on luteal phase or menstrual cycle lengths were observed. The third study (Study III) was designed to examine the effect of norfloxacin on the metabolism and excretion of P in nonpregnant females. Silastic P implants were placed subcutaneously in order to maintain constant P levels during a 10 day treatment regimen (200 mg/kg/day; ten controls, nine treated). Five of the controls and four of the norfloxacin-treated females also received 14C-P intravenously within 1 hr of the last dose of norfloxacin in order to study excretory patterns. No significant differences between control and treated groups were observed. The results of these studies combined suggest that the developmental toxic effects observed in prior studies and Study I are specific to pregnancy and directly related to placental-derived P production.",
author = "Cukierski, {M. A.} and Hendrickx, {Andrew G} and S. Prahalada and Tarantal, {Alice F} and Hess, {D. L.} and Lasley, {B. L.} and Peter, {C. P.} and R. Tarara and Robertson, {R. T.}",
year = "1992",
doi = "10.1002/tera.1420460507",
language = "English (US)",
volume = "46",
pages = "429--438",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone

AU - Cukierski, M. A.

AU - Hendrickx, Andrew G

AU - Prahalada, S.

AU - Tarantal, Alice F

AU - Hess, D. L.

AU - Lasley, B. L.

AU - Peter, C. P.

AU - Tarara, R.

AU - Robertson, R. T.

PY - 1992

Y1 - 1992

N2 - Norfloxacin, an orally active fluoroquinolone antimicrobial, has been reported to be embryolethal but not teratogenic when administered to pregnant cynomolgus macaques prior to gestational day (GD) 36 at doses ≥200 mg/kg/day. Additional studies have been performed in an effort to examine the mechanism responsible for this effect, particularly regarding the role of progesterone (P). The first study (Study I) investigated the effect of norfloxacin administration during early pregnancy (200 mg/kg/day; daily GD 20-30) in the absence of a functional corpus luteum (CL). The CL was surgically removed from 16 gravid females on GD 19 in order to focus on placental-derived P; ten were dosed with norfloxacin and six received vehicle only. Embryolethality was observed for 7/10 (70%) of the treated animals during GD 25-31 versus 0/6 (0%) for controls. A reduction in serum P was noted prior to embryonic loss, although no significant effects on chorionic gonadotropin (CG), 17β-estradiol (E2), or P or E urinary metabolites were observed. A second study (Study II) was performed in order to evaluate the capacity of norfloxacin (200 mg/kg) to reduce CL-derived P in both normally cycling and CG-stimulated nonpregnant females (ten treated, ten controls; daily for 8 days). No effects on P production or on luteal phase or menstrual cycle lengths were observed. The third study (Study III) was designed to examine the effect of norfloxacin on the metabolism and excretion of P in nonpregnant females. Silastic P implants were placed subcutaneously in order to maintain constant P levels during a 10 day treatment regimen (200 mg/kg/day; ten controls, nine treated). Five of the controls and four of the norfloxacin-treated females also received 14C-P intravenously within 1 hr of the last dose of norfloxacin in order to study excretory patterns. No significant differences between control and treated groups were observed. The results of these studies combined suggest that the developmental toxic effects observed in prior studies and Study I are specific to pregnancy and directly related to placental-derived P production.

AB - Norfloxacin, an orally active fluoroquinolone antimicrobial, has been reported to be embryolethal but not teratogenic when administered to pregnant cynomolgus macaques prior to gestational day (GD) 36 at doses ≥200 mg/kg/day. Additional studies have been performed in an effort to examine the mechanism responsible for this effect, particularly regarding the role of progesterone (P). The first study (Study I) investigated the effect of norfloxacin administration during early pregnancy (200 mg/kg/day; daily GD 20-30) in the absence of a functional corpus luteum (CL). The CL was surgically removed from 16 gravid females on GD 19 in order to focus on placental-derived P; ten were dosed with norfloxacin and six received vehicle only. Embryolethality was observed for 7/10 (70%) of the treated animals during GD 25-31 versus 0/6 (0%) for controls. A reduction in serum P was noted prior to embryonic loss, although no significant effects on chorionic gonadotropin (CG), 17β-estradiol (E2), or P or E urinary metabolites were observed. A second study (Study II) was performed in order to evaluate the capacity of norfloxacin (200 mg/kg) to reduce CL-derived P in both normally cycling and CG-stimulated nonpregnant females (ten treated, ten controls; daily for 8 days). No effects on P production or on luteal phase or menstrual cycle lengths were observed. The third study (Study III) was designed to examine the effect of norfloxacin on the metabolism and excretion of P in nonpregnant females. Silastic P implants were placed subcutaneously in order to maintain constant P levels during a 10 day treatment regimen (200 mg/kg/day; ten controls, nine treated). Five of the controls and four of the norfloxacin-treated females also received 14C-P intravenously within 1 hr of the last dose of norfloxacin in order to study excretory patterns. No significant differences between control and treated groups were observed. The results of these studies combined suggest that the developmental toxic effects observed in prior studies and Study I are specific to pregnancy and directly related to placental-derived P production.

UR - http://www.scopus.com/inward/record.url?scp=0026480891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026480891&partnerID=8YFLogxK

U2 - 10.1002/tera.1420460507

DO - 10.1002/tera.1420460507

M3 - Article

C2 - 1462247

AN - SCOPUS:0026480891

VL - 46

SP - 429

EP - 438

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 5

ER -